13D·WATCH Activist + Insider Intelligence Live feed Blog About Pilot
SCHEDULE Filed 2026-01-22 Event 2026-01-22 SEC 0001104659-26-005917 →

Fairmount Funds Management LLC Cogent Biosciences, Inc. COGT

Stake: 9.90% Shares: 16,261,918 CUSIP: 19240Q201 Class: Common Stock, $0.001 par value

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
2 13D/G filings on this issuer
1 other filing besides this one
Filer Track Record
7 filings by this filer
6 other filings in the data moat
Short Interest · settle 2026-03-31
DTC 7.10
17,425,998 shares short · +11.7% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
2 holders · $29.47M
Duquesne Family OfficePoint72 Asset Mgmt

Other 13D/G Filings on Cogent Biosciences, Inc.

FiledFormFilerStakeShares
2024-04-01 SC Fairmount Funds Management LLC view →

Other Filings by Fairmount Funds Management LLC

FiledFormIssuerStakeShares
2026-01-22 SCHEDULE Apogee Therapeutics, Inc. APGE 9.99% 6,047,027 view →
2025-03-10 SCHEDULE Oruka Therapeutics, Inc. ORKA 19.99% 8,511,824 view →
2024-04-01 SC Dianthus Therapeutics, Inc. /DE/ DNTH view →
2024-04-01 SC Viridian Therapeutics, Inc.\DE VRDN view →
2024-04-01 SC Cogent Biosciences, Inc. COGT view →
2024-04-01 SC Apogee Therapeutics, Inc. APGE view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →